TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06597721: ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours

Sponsor: Adcendo ApS · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 210 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$5,843,376

Rescue Site Savings

+$3,864,168

Unlock Full NCT06597721 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06597721 Rescue Dossier →